French (CAC) Chemicals Industry Analysis

Industry Valuation and Performance

Has the French Chemicals Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 21 Jul 2026	€119.8b	€38.3b	€3.6b	21.4x	33.2x	3.1x
Thu, 18 Jun 2026	€113.3b	€38.3b	€3.6b	20.8x	31.5x	3x
Sat, 16 May 2026	€109.3b	€38.3b	€3.6b	20.8x	30.3x	2.9x
Mon, 13 Apr 2026	€116.2b	€38.5b	€3.6b	18.5x	32.2x	3x
Wed, 11 Mar 2026	€103.3b	€38.5b	€3.6b	24.6x	28.6x	2.7x
Fri, 06 Feb 2026	€104.0b	€39.1b	€3.6b	20.4x	28.9x	2.7x
Sun, 04 Jan 2026	€98.8b	€39.1b	€3.6b	17.9x	27.4x	2.5x
Tue, 02 Dec 2025	€102.4b	€39.2b	€3.6b	18.5x	28.4x	2.6x
Thu, 30 Oct 2025	€104.3b	€39.4b	€3.7b	18.9x	28.5x	2.6x
Sat, 27 Sep 2025	€107.7b	€39.4b	€3.7b	20.7x	29.4x	2.7x
Mon, 25 Aug 2025	€113.0b	€39.3b	€3.6b	20.3x	31x	2.9x
Wed, 23 Jul 2025	€106.1b	€39.1b	€3.6b	18x	29.1x	2.7x
Fri, 20 Jun 2025	€109.8b	€39.1b	€3.6b	18.2x	30.1x	2.8x
Sun, 18 May 2025	€115.2b	€39.1b	€3.6b	18.3x	31.6x	2.9x
Tue, 15 Apr 2025	€105.4b	€39.0b	€3.7b	18.4x	28.7x	2.7x
Thu, 13 Mar 2025	€112.3b	€39.0b	€3.7b	22.7x	30.5x	2.9x
Sat, 08 Feb 2025	€106.1b	€38.9b	€3.4b	22.2x	31x	2.7x
Mon, 06 Jan 2025	€97.0b	€39.0b	€3.4b	19.5x	28.4x	2.5x
Wed, 04 Dec 2024	€100.5b	€39.3b	€3.4b	19.7x	29.7x	2.6x
Fri, 01 Nov 2024	€104.5b	€39.2b	€3.4b	20.2x	30.8x	2.7x
Sun, 29 Sep 2024	€111.3b	€39.4b	€3.4b	19.2x	33.2x	2.8x
Tue, 27 Aug 2024	€104.8b	€39.4b	€3.3b	21.2x	31.3x	2.7x
Thu, 25 Jul 2024	€104.6b	€39.9b	€3.4b	21.6x	30.8x	2.6x
Sat, 22 Jun 2024	€103.0b	€39.9b	€3.4b	21.5x	30.3x	2.6x
Mon, 20 May 2024	€107.3b	€39.9b	€3.4b	23.5x	31.9x	2.7x
Wed, 17 Apr 2024	€108.8b	€40.1b	€3.4b	24.1x	31.7x	2.7x
Fri, 15 Mar 2024	€111.6b	€40.1b	€3.4b	17x	32.4x	2.8x
Sun, 11 Feb 2024	€97.7b	€42.5b	€3.5b	18.4x	27.6x	2.3x
Tue, 09 Jan 2024	€99.9b	€42.5b	€3.5b	19.1x	28.3x	2.4x
Thu, 07 Dec 2023	€100.1b	€42.4b	€3.5b	17.3x	28.5x	2.4x
Sat, 04 Nov 2023	€94.6b	€43.1b	€3.6b	13.3x	26.1x	2.2x
Mon, 02 Oct 2023	€93.3b	€43.1b	€3.6b	13.7x	25.7x	2.2x
Wed, 30 Aug 2023	€96.8b	€43.1b	€3.6b	14.8x	26.5x	2.2x
Fri, 28 Jul 2023	€92.8b	€44.1b	€3.5b	15.1x	26.7x	2.1x

Current Industry PE

Investors are optimistic on the French Chemicals industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 33.2x which is higher than its 3-year average PE of 29.6x.

The 3-year average PS ratio of 2.6x is lower than the industry's current PS ratio of 3.1x.

Past Earnings Growth

The earnings for companies in the Chemicals industry have remained mostly flat over the last three years.
Meanwhile revenues for these companies have declined 4.5% per year.
This means that the cost of doing business could be reducing since sales have declined but profits have remained steady.

Industry Trends

Which industries have driven the changes within the French Materials industry?


FR Market	-0.37%
Materials	0.29%
Chemicals	0.39%
Fertilizers and Agricultural Chemicals	2.99%
Commodity Chemicals	2.80%
Industrial Gases	0.54%
Diversified Chemicals	-2.40%
Specialty Chemicals	-2.74%

Industry PE

Investors are most optimistic about the Specialty Chemicals industry which is trading above its 3-year average PE ratio of 25.6x.

Analysts are expecting annual earnings growth of 32.3%, which is higher than its past year's earnings decline of 1.0% per year.

Forecasted Growth

Analysts are most optimistic on the Specialty Chemicals industry, expecting annual earnings growth of 32% over the next 5 years.
This is better than its past earnings decline of 1.0% per year.

In contrast, the Industrial Gases industry is expected to see its earnings grow by 9.7% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
AI L'Air Liquide	€177.70	0.5% +€609.4m	13.6%	PE32.1x
EXPL EPC Groupe	€286.00	4.0% +€23.5m	42.3%	PE21.4x
MLPRX Parx Materials	€0.42	7.7% +€312.7k	75.0%	PS2432x
ALPVL Plastiques du Val de Loire	€2.65	0.4% +€220.7k	126.5%	PS0.08x
ALFLO SAS Florentaise	€0.69	3.0% +€164.7k	25.5%	n/a

Amoéba Receives Marketing Authorization For Biofungicide AXPERA In France

Amoéba has obtained marketing authorization for its biofungicide AXPERA in France. This first authorisation, granted by ANSES following the evaluation conducted by France in its capacity as rapporteur Member State for European Union, now allows the other concerned Member States concerned to proceed with and finalise their national authorisation procedures in the coming weeks and months, according to each country’s specific timelines. This authorization marks the launch of the commercialization phase for AXPERA in partnership with Koppert, initially in France and then in the other European countries covered by the agreement once approvals have been granted by the relevant national authorities. AXPERA is approved by ANSES as a fungicide that acts by inhibiting the germination of fungal spores. The product is now approved for the following uses: Grapes (wine and table grapes) for Downy mildew and Powdery mildew in open field; Cucurbits for Downy mildew in open field and Powdery mildew in open field and protected conditions; Tomatoes for Late blight in open field and protected conditions and Powdery mildew in protected conditions; Eggplant for Late blight in open field and protected conditions and Powdery mildew in protected conditions; Basil for Downy mildew in open field; Lettuce (including baby leafs) for Downy mildew in open field; Artichokes for Downy mildew in open field. The product is intended for preventive use; it can be used alone, as part of a treatment program, or in combination with other fungicides approved for use against the specific disease. AXPERA is approved as a low-risk product and can be used in both conventional and organic agriculture in accordance with applicable regulations. The authorized application conditions of use contribute to the product’s appeal to farmers by combining protection, effectiveness, and ease of use. In particular, they result in the shortest re-entry period and pre-harvest interval, as well as the shortest safety distances granted by ANSES for a plant protection product. The active ingredient of AXPERA, the “Lysate of Willaertia magna C2c Maky,” is included on the list of active ingredients exempt from maximum residue limits (MRLs), offering a significant regulatory advantage: it facilitates the marketing of crops by eliminating the need for testing on treated foodstuffs. The AXPERA product is intended to be included on the French list of biocontrol products. This inclusion would offer several advantages, in particular: Meeting growing environmental and health expectations; Facilitating procedures, certifications, and specifications that promote products respectful of the environment and consumers, such as the “High Environmental Value” (Haute Valeur Environnementale) or “Zero Pesticide Residue” labels; Enhancing the product’s social acceptability and value among farmers, distributors, and industry sectors; Integrating the product into the French National Biocontrol Strategy; Getting authorization for commercial advertising. Now that the product has been approved in France - which acted as the zonal rapporteur Member State for the product’s evaluation - the other concerned Member States will be able to finalize their national approval procedures: Applications for open-field use have already been submitted in Portugal, Spain, Italy, and Greece. Applications for protected uses have already been submitted in Portugal, Spain, Italy, Greece, Belgium, Poland, and Germany. These protected uses will also be the subject of a mutual recognition application in 12 additional Member States, with a view to market access starting in 2027. This first marketing authorization in Europe, valid for a renewable 15-year period, thus serves as a major lever, facilitating future geographic expansions as well as the extension of uses, both in terms of crops and targeted diseases.

French (CAC) Chemicals Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

First half 2026 earnings released

Price target decreased by 8.6% to €0.64

Dividend increased to €3.00

AI: Fair Value View Weighs AI Gas Investments Against Execution Risks

New minor risk - Insider selling

Afyren Resumes Production At Afyren Neoxy Plant After Technical Shutdown

Amoéba Receives Marketing Authorization For Biofungicide AXPERA In France

New minor risk - Market cap size

Arkema Starts Up 15% PVDF Expansion to Meet Rising Battery and Chip Demand

Upcoming dividend of €12.00 per share

New major risk - Financial data availability

Serge Ferrari Group Discontinues Pet Spinning Operations At Tersuisse Site and Reduces 62 Jobs

New major risk - Financial data availability